Peer-reviewed articleOpen access

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.

Blest-Hopley G, Amit BH, O'Neill A, Ruffell SGD

Frontiers in psychiatryMay 12, 2023License: open accessUnited Kingdom, Israel, Ireland, Peru, Australia0 citationsDOI: 10.3389/fpsyt.2023.1191970

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Psilocybin

Keywords

CannabisCannabinoidsPsychedelicsHallucinogenic

View paper Full text (PDF)

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Association of Psilocybin Use in Adolescents with Major Depressive Episode

Shah K, Trivedi C, Kamrai D +2

Europe PMC2022

ArticlePsilocybin

Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain.

Spain A, Howarth C, Khrapitchev AA +3

Europe PMC2015

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023